Titre : Vinblastine

Vinblastine : Questions médicales fréquentes

Termes MeSH sélectionnés :

Lactulose
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Vinblastine : Questions médicales les plus fréquentes", "headline": "Vinblastine : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Vinblastine : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-05-10", "dateModified": "2025-02-04", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Vinblastine" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Alcaloïdes de Vinca", "url": "https://questionsmedicales.fr/mesh/D014748", "about": { "@type": "MedicalCondition", "name": "Alcaloïdes de Vinca", "code": { "@type": "MedicalCode", "code": "D014748", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.496.500.500.681.827" } } }, "about": { "@type": "MedicalCondition", "name": "Vinblastine", "alternateName": "Vinblastine", "code": { "@type": "MedicalCode", "code": "D014747", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "None None", "url": "https://questionsmedicales.fr/author/None%20None", "affiliation": { "@type": "Organization", "name": "" } }, { "@type": "Person", "name": "Christine Chevreau", "url": "https://questionsmedicales.fr/author/Christine%20Chevreau", "affiliation": { "@type": "Organization", "name": "Department of Medicine, Oncopole, Toulouse, France." } }, { "@type": "Person", "name": "Stéphane Culine", "url": "https://questionsmedicales.fr/author/St%C3%A9phane%20Culine", "affiliation": { "@type": "Organization", "name": "Department of Medical Oncology Saint-Louis University Hospital, AP-HP, Paris, France. Electronic address: stephane.culine@aphp.fr." } }, { "@type": "Person", "name": "Gwenaelle Gravis", "url": "https://questionsmedicales.fr/author/Gwenaelle%20Gravis", "affiliation": { "@type": "Organization", "name": "Department of Medical Oncology, Paoli Calmettes Institute, Marseille, France." } }, { "@type": "Person", "name": "Florence Joly", "url": "https://questionsmedicales.fr/author/Florence%20Joly", "affiliation": { "@type": "Organization", "name": "Department of Medical Oncology, François Baclesse Cancer Center, Caen, France." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Lactulose Ingestion Induces a Rapid Increase in Genus", "datePublished": "2022-08-26", "url": "https://questionsmedicales.fr/article/36144321", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/microorganisms10091719" } }, { "@type": "ScholarlyArticle", "name": "Effects of nutritional therapy on gastrointestinal microbial digestion and barrier defense markers in elderly patients with diabetes.", "datePublished": "2023-10-11", "url": "https://questionsmedicales.fr/article/37821689", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s40520-023-02518-4" } }, { "@type": "ScholarlyArticle", "name": "Management of minimal and overt hepatic encephalopathy with branched-chain amino acids: a review of the evidence.", "datePublished": "2023-06-15", "url": "https://questionsmedicales.fr/article/37395232", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/MEG.0000000000002595" } }, { "@type": "ScholarlyArticle", "name": "The Effects of a Very-Low-Calorie Ketogenic Diet on the Intestinal Barrier Integrity and Function in Patients with Obesity: A Pilot Study.", "datePublished": "2023-05-30", "url": "https://questionsmedicales.fr/article/37299524", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/nu15112561" } }, { "@type": "ScholarlyArticle", "name": "Small Intestinal Bacterial Overgrowths and Intestinal Methanogen Overgrowths Breath Testing in a Real-Life French Cohort.", "datePublished": "2023-04-01", "url": "https://questionsmedicales.fr/article/36515897", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.14309/ctg.0000000000000556" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Composés hétérocycliques", "item": "https://questionsmedicales.fr/mesh/D006571" }, { "@type": "ListItem", "position": 3, "name": "Composés hétérocycliques à cycles fusionnés", "item": "https://questionsmedicales.fr/mesh/D000072471" }, { "@type": "ListItem", "position": 4, "name": "Composés hétérobicycliques", "item": "https://questionsmedicales.fr/mesh/D006574" }, { "@type": "ListItem", "position": 5, "name": "Indolizine", "item": "https://questionsmedicales.fr/mesh/D007212" }, { "@type": "ListItem", "position": 6, "name": "Indolizidines", "item": "https://questionsmedicales.fr/mesh/D054836" }, { "@type": "ListItem", "position": 7, "name": "Alcaloïdes indoliques", "item": "https://questionsmedicales.fr/mesh/D026121" }, { "@type": "ListItem", "position": 8, "name": "Alcaloïdes formés par condensation de sécologanine et de tryptamine", "item": "https://questionsmedicales.fr/mesh/D046948" }, { "@type": "ListItem", "position": 9, "name": "Alcaloïdes de Vinca", "item": "https://questionsmedicales.fr/mesh/D014748" }, { "@type": "ListItem", "position": 10, "name": "Vinblastine", "item": "https://questionsmedicales.fr/mesh/D014747" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Vinblastine - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Vinblastine", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-04", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Vinblastine", "description": "Comment la vinblastine est-elle utilisée dans le diagnostic du cancer ?\nQuels tests précèdent l'administration de vinblastine ?", "url": "https://questionsmedicales.fr/mesh/D014747?mesh_terms=Lactulose&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Vinblastine", "description": "Quels sont les effets secondaires courants de la vinblastine ?\nLa vinblastine provoque-t-elle des douleurs ?", "url": "https://questionsmedicales.fr/mesh/D014747?mesh_terms=Lactulose&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Vinblastine", "description": "La vinblastine a-t-elle un rôle préventif dans le cancer ?\nPeut-on prévenir les effets secondaires de la vinblastine ?", "url": "https://questionsmedicales.fr/mesh/D014747?mesh_terms=Lactulose&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Vinblastine", "description": "Dans quels types de cancer la vinblastine est-elle utilisée ?\nComment la vinblastine est-elle administrée ?", "url": "https://questionsmedicales.fr/mesh/D014747?mesh_terms=Lactulose&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Vinblastine", "description": "Quelles complications peuvent survenir avec la vinblastine ?\nLa vinblastine peut-elle affecter la moelle osseuse ?", "url": "https://questionsmedicales.fr/mesh/D014747?mesh_terms=Lactulose&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Vinblastine", "description": "Qui est à risque d'effets indésirables avec la vinblastine ?\nLes enfants peuvent-ils prendre de la vinblastine ?", "url": "https://questionsmedicales.fr/mesh/D014747?mesh_terms=Lactulose&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment la vinblastine est-elle utilisée dans le diagnostic du cancer ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "La vinblastine n'est pas un outil de diagnostic, mais un traitement pour les cancers diagnostiqués." } }, { "@type": "Question", "name": "Quels tests précèdent l'administration de vinblastine ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests sanguins et d'imagerie sont effectués pour évaluer la maladie avant le traitement." } }, { "@type": "Question", "name": "Quels sont les effets secondaires courants de la vinblastine ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires incluent nausées, vomissements, fatigue et perte de cheveux." } }, { "@type": "Question", "name": "La vinblastine provoque-t-elle des douleurs ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Elle peut causer des douleurs musculaires ou articulaires, mais ce n'est pas systématique." } }, { "@type": "Question", "name": "La vinblastine a-t-elle un rôle préventif dans le cancer ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Non, la vinblastine est un traitement et ne prévient pas le développement du cancer." } }, { "@type": "Question", "name": "Peut-on prévenir les effets secondaires de la vinblastine ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Des médicaments antiémétiques peuvent aider à réduire les nausées causées par la vinblastine." } }, { "@type": "Question", "name": "Dans quels types de cancer la vinblastine est-elle utilisée ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Elle est utilisée pour traiter les lymphomes, le cancer du poumon et le cancer du testicule." } }, { "@type": "Question", "name": "Comment la vinblastine est-elle administrée ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "La vinblastine est généralement administrée par injection intraveineuse sous supervision médicale." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec la vinblastine ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des complications incluent des infections, des saignements et des problèmes neurologiques." } }, { "@type": "Question", "name": "La vinblastine peut-elle affecter la moelle osseuse ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la vinblastine peut entraîner une dépression de la moelle osseuse, réduisant les globules blancs." } }, { "@type": "Question", "name": "Qui est à risque d'effets indésirables avec la vinblastine ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Les patients avec des antécédents de maladies cardiaques ou hépatiques sont à risque accru." } }, { "@type": "Question", "name": "Les enfants peuvent-ils prendre de la vinblastine ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la vinblastine peut être administrée aux enfants, mais avec précaution et surveillance." } } ] } ] }

Sources (96 au total)

Effects of nutritional therapy on gastrointestinal microbial digestion and barrier defense markers in elderly patients with diabetes.

We sought to investigate the effects of gastrointestinal nutrition therapy on gastrointestinal microbial digestion and barrier defense markers in elderly patients with diabetes.... A total of 120 elderly patients with type 2 diabetes were enrolled at our hospital between January 2020 and December 2022. The participants in this study were randomly allocated into either the nutrit... The nutrition group demonstrated a higher proportion of patients achieving HbA1c < 7% compared to the control group (P < 0.05). Moreover, the nutrition group exhibited a greater reduction in fasting a... Personalized gastrointestinal nutrition therapy was found to enhance the production of short-chain fatty acids and preserve intestinal permeability, leading to improved gastrointestinal microbial dige...

Small Intestinal Bacterial Overgrowths and Intestinal Methanogen Overgrowths Breath Testing in a Real-Life French Cohort.

Breath testing has become a widely used tool to diagnose small intestinal bacterial overgrowths (SIBOs) and intestinal methanogen overgrowths (IMOs) in clinical settings. Owing to the heterogeneity in... Breath test data and symptoms of 331 patients were assessed for SIBO/IMO using the H 2 /CH 4 lactulose breath test (LBT). Wilcoxon test or χ 2 test were used to compare patients with SIBO/IMO with pat... Among the 186 (68.1%) patients tested positive for an overgrowth with 40.3%, 47.3%, and 12.4% for H 2 +, CH 4 + and CH 4 +/H 2 +, respectively, the presence of diarrhea was significantly increased in ... There are little discriminating symptoms that can help the clinician to identify patients likely to have a SIBO/IMO. However, SIBO/IMOs remain a common disorder widely underdiagnosed that need further...

Hepatic encephalopathy - recent advances in treatment and diagnosis.

Hepatic encephalopathy (HE) is a peculiar kind of brain dysfunction typical of liver cirrhosis characterized by nonspecific neurological and psychiatric manifestations. HE ranges from minimal hepatic ... The most widely empirical pharmacological approach consists of non-absorbable antibiotics (rifaximin) and non-absorbable disaccharides (lactulose, lactitol per os and per enemas). Other agents (includ... Gray areas and future needs remain the therapeutic approach to MHE and issues in the design of therapeutic studies for HE which have been extensively discussed in this review....

Efficacy evaluation of probiotics combined with prebiotics in patients with clinical hypothyroidism complicated with small intestinal bacterial overgrowth during the second trimester of pregnancy.

To explore the effect of probiotics combined with prebiotics on clinical hypothyroidism during pregnancy combined with small intestinal bacterial overgrowth.... (1) In total, 441 pregnant women were included in this study. A total of 231 patients with clinical hypothyroidism during the second trimester of pregnancy and 210 normal pregnant women were enrolled ... (1) The positive rates of SIBO in pregnant women in the clinical hypothyroidism group and control group were 48.5% and 24.8%, respectively. (2) The incidence of abdominal distention and constipation i... Probiotics combined with prebiotics are effective in the treatment of pregnant patients with clinical hypothyroidism complicated with SIBO, providing a new idea to treat pregnant patients with clinica...

The effect of rugby training on indirect markers of gut permeability and gut damage in academy level rugby players.

To assess indirect markers of intestinal endothelial cell damage and permeability in academy rugby players in response to rugby training at the beginning and end of preseason.... Blood and urinary measures (intestinal fatty acid binding protein and lactulose:rhamnose) as measures of gastrointestinal cell damage and permeability were taken at rest and after a standardised colli... Following the rugby training session at the start of preseason, there was an increase (median; interquartile range) in intestinal fatty acid binding protein (2140; 1260-2730 to 3245; 1985-5143 pg/ml, ... Rugby training resulted in increased intestinal endothelial cell damage and permeability compared to rest. A similar magnitude of effect was observed after six weeks of pre-season training. This was n...

Possible mediators of metabolic endotoxemia in women with obesity and women with obesity-diabetes in The Gambia.

Translocation of bacterial debris from the gut causes metabolic endotoxemia (ME) that results in insulin resistance, and may be on the causal pathway to obesity-related type 2 diabetes. To guide inter... In lean women (n = 48; fat mass index (FMI) 9.6 kg/m... The LM ratio did not differ between groups. LPS levels were 57% higher in the obesity-diabetes group (P < 0.001), but, contrary to the chylomicron transfer hypothesis, levels significantly declined fo... Raised levels of LPS and IL-6 in women with obesity-diabetes and evidence of macrophage activation in adipose tissue support the concept of metabolic endotoxemia-mediated inflammation, but we found no...

Comparative Study of Prebiotics for Infants Using a Fecal Culture System: Insights into Responders and Non-Responders.

The gut microbiota of breast-fed infants is dominated by infant-type human-residential bifidobacteria (HRB) that contribute to infant health; thus, it is crucial to develop infant formulas that promot... We compared various non-digestible prebiotic oligosaccharides and their combinations using a fecal culture system to explore which candidates could promote the growth of all infant-type HRB and rarely... No single oligosaccharide effectively promoted the growth of all infant-type HRB, although GOS promoted the growth of HRB other than... This study can aid in developing infant formulas that help align the gut microbiota of formula-fed infants with that of breastfed infants....